Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

Publisher Name :
Date: 01-Jun-2018
No. of pages: 125

Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common symptoms of psoriasis include inflammation, swelling, and patches of red, itchy, flaky skin called skin lesions.

The most common sites of involvement are the scalp, elbows and knees, followed by nails, hands, feet and trunk. It is estimated that up to 30% of people with psoriasis eventually develop psoriatic arthritis. Psoriasis is a serious skin condition that has a significant negative impact on patients’ quality of life, interfering in many aspects of professional and social life.

Men and women are equally likely to get it, and the onset of psoriasis can occur at any age. However, the age of onset frequency proved to be bimodal the first before 40 years of age and the second between 50 and 60 years of age. The extent and severity of the disease varies greatly between patients and often varies within individuals over the course of time.

There are different types of psoriasis, the most common being plaque psoriasis. Around 125 million people worldwide have psoriasis, of which 80% have plaque psoriasis. The current marketed drug landscape in psoriasis includes topical agents, systemic therapies (such as acitretin, cyclosporine and methotrexate) and biologic therapies. In recent years, the discovery of new immunological factors and better understanding of psoriasis have fundamentally changed the treatment of psoriasis and created new biological drugs against specific immunological elements that cause psoriasis.

Both IL-17 and IL-23 are promising targets in the treatment of moderate to severe plaque psoriasis. The biologic drugs targeting these cytokines and their receptors have proven to be effective and safe in clinical trials and have offered greater efficacy than pre-existing biologics, making them an attractive option for use prior to other biologics.

Therefore, during the forecast period, the dominance of TNF-α inhibitors (adalimumab, infliximab and etanercept) and interleukin (IL)-12/23 inhibitor ustekinumab will be challenged by the highly effective IL-17 and IL-23 inhibitor therapies. The late-stage psoriasis pipeline is composed of promising targeted therapies that have potential to achieve approval and launch during the forecast period.

These include Sun Pharma’s tildrakizumab, AbbVie’s risankizumab, Welichem Biotech’s Tapinarof, and UCB’s bimekizumab and certolizumab pegol. These new drugs will supplement current market leaders and offer broader therapeutic options.

Scope


  • The Asia-Pacific psoriasis market will be valued at $1,997.3m in 2024, growing from $933.1m in 2017, at a compound annual growth rate (CAGR) of 11.5%.

  • What are the key factors driving the Asia-Pacific psoriasis treatment market?

  • How will novel IL-23 inhibitor therapy Tremfya, which holds first-to-market advantage, contribute to growth?

  • What will be the impact of the new IL-17 and IL-23 inhibitor therapies?

  • How will branded therapies be affected by upcoming pipeline therapies?

  • The psoriasis pipeline contains a range of molecule types and molecular targets, including those that are well established in psoriasis and novel target therapies.

  • Which molecular targets appear most frequently in the pipeline?

  • Is there potential for pipeline molecules to address unmet needs within the psoriasis market?

  • Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

  • How have the late-stage therapies performed in clinical trials?

  • Which classes of drugs are most prominent in the pipeline?

  • How will the approval of risankizumab and tildrakizumab, which hold a key advantage in terms of dosing schedule over IL-23 competitor Tremfya, affect the competitive landscape?

  • Various drivers and barriers will influence the market over the forecast period.

  • What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?

  • What factors are most likely to drive the market in these countries?

  • What licensing and co-development deals have occurred within this therapy area since 2007?


Reasons to buy


  • Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.

  • Visualize the composition of the psoriasis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

  • Analyze the psoriasis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

  • Predict psoriasis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

  • Identify commercial opportunities in the psoriasis deals landscape by analyzing trends in licensing and co-development deals.

Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.3.1 Skin Manifestations 12
2.3.2 Psychological Impact 12
2.4 Etiology, Co-morbidities and Risk Factors 13
2.4.1 Genetics 13
2.4.2 Psoriatic Arthritis 13
2.4.3 Mental Health Disorders 13
2.4.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 14
2.4.5 Infections 15
2.4.6 Koebner Phenomenon 15
2.4.7 Other Immune-Mediated Diseases 15
2.5 Pathophysiology 15
2.6 Diagnosis 16
2.7 Prognosis 16
2.8 Treatment and Management 16
2.8.1 Pharmacological Therapies 17
2.8.2 Non-pharmacological Therapies 18
2.8.3 Combination and Rotational Therapies 19
2.8.4 Quality of Life Assessments 19

3 Marketed Products 20
3.1 Overview 20
3.1.1 Tremfya (guselkumab) - Janssen Biotech 21
3.1.2 Cosentyx (secukinumab) - Novartis 22
3.1.3 Otezla (apremilast) - Celgene 24
3.1.4 Alzumab (Itolizumab) - Biocon 25
3.1.5 Diavobet (calcipotriene and betamethasone dipropionate) - LEO Pharma 26
3.1.6 Lumicef (brodalumab) - Kyowa Hakko Kirin 27
3.1.7 Taltz (ixekizumab) - Eli Lilly 28
3.1.8 Stelara (ustekinumab) - Janssen Biotech 29
3.1.9 Enbrel (Etanercept) - Amgen 31
3.1.10 Remicade (Infliximab) - Janssen Biotech 32
3.1.11 Humira (Adalimumab) - AbbVie 33
3.1.12 Methotrexate 34
3.1.13 Cyclosporine 35
3.1.14 Acitretin 37
3.2 Comparative Efficacy and Safety of Marketed Products 38

4 Pipeline Analysis 40
4.1 Overview 40
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 41
4.3 Pipeline by Molecular Target 42
4.4 Promising Pipeline Candidates 44
4.4.1 Tildrakizumab - Sun Pharma 44
4.4.2 Risankizumab - AbbVie 46
4.4.3 Tapinarof - Welichem Biotech 48
4.4.4 Bimekizumab - UCB 49
4.4.5 Certolizumab Pegol - UCB 51
4.5 Comparative Efficacy and Safety of Pipeline Products 53
4.6 Product Competitiveness Framework 54

5 Clinical Trial Analysis 56
5.1 Failure Rate 56
5.1.1 Overall Failure Rate 56
5.1.2 Failure Rate by Phase and Molecule Type 58
5.1.3 Failure Rate by Phase and Molecular Target 58
5.2 Clinical Trial Size 59
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 59
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 60
5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 61
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 62
5.3 Clinical Trial Duration 63
5.3.1 Clinical Trial Duration by Molecule Type 63
5.3.2 Clinical Trial Duration by Molecular Target 64
5.4 Competitive Clinical Trials Metrics Analysis 65

6 Multi-scenario Forecast 67
6.1 Geographical Markets 67
6.2 Asia-Pacific Market 67
6.3 India 70
6.3.1 Treatment Usage Patterns 70
6.3.2 Annual Cost of Therapy 71
6.3.3 Market Size 72
6.4 China 73
6.4.1 Treatment Usage Patterns 73
6.4.2 Annual Cost of Therapy 74
6.4.3 Market Size 74
6.5 Australia 75
6.5.1 Treatment Usage Patterns 75
6.5.2 Annual Cost of Therapy 76
6.5.3 Market Size 77
6.6 South Korea 78
6.6.1 Treatment Usage Patterns 78
6.6.2 Annual Cost of Therapy 79
6.6.3 Market Size 80
6.7 Japan 81
6.7.1 Treatment Usage Patterns 81
6.7.2 Annual Cost of Therapy 82
6.7.3 Market Size 82

7 Drivers and Barriers 84
7.1 Drivers 84
7.1.1 Increasing Support and Assistance from the Healthcare Systems 84
7.1.2 Rising Prevalence 84
7.1.3 Potential for Innovative Pipeline Molecules to Address Significant Unmet Need 84
7.1.4 Increasing Acceptance of Biologics and Biosimilars 84
7.2 Barriers 85
7.2.1 Use of Phototherapy and Traditional Medicines 85
7.2.2 Low Compliance and Treatment Discontinuation 85
7.2.3 Regulatory Submissions and Clinical Trial Requirement 85
7.2.4 High Prices of Therapeutics to Slow Down Market Growth 85
7.2.5 Growing Competition to Hinder Uptake of Pipeline Drugs 86

8 Deals and Strategic Consolidations 87
8.1 Licensing Deals 87
8.1.1 Deals by Region and Value 87
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 88
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 89
8.1.4 Key Licensing Deals 92
8.2 Co-development Deals 94
8.2.1 Deals by Region and Value 94
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 95
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 95
8.2.4 Key Co-development Deals 98

9 Appendix 100
9.1 All Pipeline Drugs by Stage of Development 100
9.1.1 Discovery 100
9.1.2 Preclinical 102
9.1.3 IND/CTA-filed 105
9.1.4 Phase I 106
9.1.5 Phase II 107
9.1.6 Phase III 109
9.1.7 Pre-registration 110
9.2 Market Forecasts to 2024 110
9.2.1 Asia-Pacific 110
9.2.2 India 111
9.2.3 China 111
9.2.4 Australia 111
9.2.5 South Korea 112
9.2.6 Japan 112
9.3 Bibliography 112
9.4 Abbreviations 120
9.5 Research Methodology 121
9.5.1 Secondary Research 122
9.5.2 Marketed Product Profiles 122
9.5.3 Late-Stage Pipeline Candidates 122
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 122
9.5.5 Product Competitiveness Framework 123
9.5.6 Pipeline Analysis 123
9.5.7 Forecasting Model 123
9.5.8 Deals Data Analysis 124
9.6 Contact Us 125
9.7 Disclaimer 125

List of Tables

Table 1: Psoriasis Therapeutics Market, APAC, Types of Psoriasis 10
Table 2: Psoriasis Therapeutics Market, APAC, Age Distribution of Psoriasis Prevalence in South Korea 12
Table 3: Psoriasis Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2017 93
Table 4: Psoriasis Therapeutics Market, Global, Co-development Deals, 2007-2017 99
Table 5: Psoriasis Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 100
Table 6: Psoriasis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 102
Table 7: Psoriasis Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018 105
Table 8: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 106
Table 9: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 107
Table 10: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 109
Table 11: Psoriasis Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018 110
Table 12: Psoriasis Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024 110
Table 13: Psoriasis Therapeutics Market, India, Market Forecast, 2017-2024 111
Table 14: Psoriasis Therapeutics Market, China, Market Forecast, 2017-2024 111
Table 15: Psoriasis Therapeutics Market, Australia, Market Forecast, 2017-2024 111
Table 16: Psoriasis Therapeutics Market, South Korea, Market Forecast, 2017-2024 112
Table 17: Psoriasis Therapeutics Market, Japan, Market Forecast, 2017-2024 112

List of Figures

Figure 1: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 39
Figure 2: Pipeline for Psoriasis Therapeutics, Global, 2018 42
Figure 3: Pipeline for Psoriasis Therapeutics by Molecular Target, Global, 2018 44
Figure 4: Psoriasis Therapeutics Market, APAC, Tildrakizumab Forecast ($m), 2018-2024 46
Figure 5: Psoriasis Therapeutics Market, APAC, Risankizumab Forecast ($m), 2019-2024 48
Figure 6: Psoriasis Therapeutics Market, APAC, Bimekizumab Forecast ($m), 2022-2024 51
Figure 7: Psoriasis Therapeutics Market, APAC, Certolizumab Pegol Market ($m), 2021-2024 53
Figure 8: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 54
Figure 9: Psoriasis Therapeutics Market, Competitor Matrix for Psoriasis Marketed and Pipeline Products 55
Figure 10: Psoriasis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017 57
Figure 11: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017 58
Figure 12: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017 59
Figure 13: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017 60
Figure 14: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017 61
Figure 15: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017 62
Figure 16: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017 63
Figure 17: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017 64
Figure 18: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017 65
Figure 19: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 65
Figure 20: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 66
Figure 21: Psoriasis Therapeutics Market, Asia Pacific, Treatment Usage Patterns (‘000), 2017-2024 68
Figure 22: Psoriasis Therapeutics Market, Asia Pacific, Market Size ($m), 2017-2024 69
Figure 23: Psoriasis Therapeutics Market, India, Treatment Usage Patterns (’000), 2017-2024 70
Figure 24: Psoriasis Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 71
Figure 25: Psoriasis Therapeutics Market, India, Market Size ($m), 2017-2024 72
Figure 26: Psoriasis Therapeutics Market, China, Treatment Usage Patterns (‘000), 2017-2024 73
Figure 27: Psoriasis Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 74
Figure 28: Psoriasis Therapeutics Market, China, Market Size ($m), 2017-2024 75
Figure 29: Psoriasis Therapeutics Market, Australia, Treatment Usage Patterns (‘000), 2017-2024 76
Figure 30: Psoriasis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 77
Figure 31: Psoriasis Therapeutics Market, Australia, Market Size ($m), 2017-2024 78
Figure 32: Psoriasis Therapeutics Market, South Korea, Treatment Usage Patterns (‘000), 2017-2024 79
Figure 33: Psoriasis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 79
Figure 34: Psoriasis Therapeutics Market, South Korea, Market Size ($m), 2017-2024 80
Figure 35: Psoriasis Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2017-2024 81
Figure 36: Psoriasis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 82
Figure 37: Psoriasis Therapeutics Market, Japan, Market Size ($m), 2017-2024 83
Figure 38: Psoriasis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2017 88
Figure 39: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017 89
Figure 40: Psoriasis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017 90
Figure 41: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2017 91
Figure 42: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2017 92
Figure 43: Psoriasis Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2017 94
Figure 44: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017 95
Figure 45: Psoriasis Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017 96
Figure 46: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2017 97
Figure 47: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2017 98

  • Global Enzyme Replacement Therapy Market Growth (Status and Outlook) 2019-2024
    Published: 22-Feb-2019        Price: US 3660 Onwards        Pages: 136
    Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme. The classification of enzyme replacement therapy includes injectable agents and oral agents, and the revenue proportion of injectable agents in 2017 is about 62.38%, and the proportion is in increasing trend from 2013 to 2017. North America is the larges......
  • Global Infantile Spasms Therapeutics Market Growth 2019-2024
    Published: 22-Feb-2019        Price: US 3660 Onwards        Pages: 130
    An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with s......
  • Musculoskeletal Disorders Therapeutics Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 20-Feb-2019        Price: US 3000 Onwards        Pages: 147
    Musculoskeletal Disorders Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Musculoskeletal Disorders Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Musculoskeletal Disorders Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides a......
  • Global Anti-inflammatory Therapeutics Market Research Report 2019
    Published: 20-Feb-2019        Price: US 2900 Onwards        Pages: 90
    Anti-inflammatory therapeutics are primarily used to reduce inflammation. These drugs are types of analgesics that are used for reducing pain. The global anti-inflammatory therapeutics market will grow steadily at a CAGR of over 6% by 2021. This market research analysis identifies the increase in the prevalence of immune-mediated inflammatory disease (IMID) as one of the primary growth factors for this market. IMID includes a group of disabling conditions that share a common inflammatory ......
  • Global Microbiome Therapeutics Market Growth 2019-2024
    Published: 20-Feb-2019        Price: US 3660 Onwards        Pages: 175
    The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bact......
  • Global Acute Ischemic Stroke Therapeutics Market Research Report 2019
    Published: 20-Feb-2019        Price: US 2900 Onwards        Pages: 98
    AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternat......
  • Global Venous Leg Ulcers Treatment Market Insights, Forecast to 2025
    Published: 19-Feb-2019        Price: US 3900 Onwards        Pages: 118
    The global Venous Leg Ulcers Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Venous Leg Ulcers Treatment market based on company, product type, end user and key regions. This report studies the global market size of Venous Leg Ulcers Treatment in key regions like North America, Europe, Asia Pacific, Central & South......
  • Global Substance Abuse Treatment Market Insights, Forecast to 2025
    Published: 19-Feb-2019        Price: US 3900 Onwards        Pages: 119
    The global Substance Abuse Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Substance Abuse Treatment market based on company, product type, end user and key regions. This report studies the global market size of Substance Abuse Treatment in key regions like North America, Europe, Asia Pacific, Central & South Ameri......
  • Ozone Treatment Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 18-Feb-2019        Price: US 3000 Onwards        Pages: 137
    Ozone Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Ozone Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Ozone Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Ozone Treatment ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs